1. Home
  2. VTSI vs KLRS Comparison

VTSI vs KLRS Comparison

Compare VTSI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirTra Inc.

VTSI

VirTra Inc.

HOLD

Current Price

$4.26

Market Cap

53.2M

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$9.49

Market Cap

46.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTSI
KLRS
Founded
1993
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.2M
46.0M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
VTSI
KLRS
Price
$4.26
$9.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$7.00
$20.67
AVG Volume (30 Days)
26.7K
57.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$16,524,225.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.39
N/A
P/E Ratio
$47.39
N/A
Revenue Growth
5.57
N/A
52 Week Low
$3.57
$2.14
52 Week High
$7.47
$11.90

Technical Indicators

Market Signals
Indicator
VTSI
KLRS
Relative Strength Index (RSI) 44.62 45.83
Support Level $4.25 $8.08
Resistance Level $5.15 $10.64
Average True Range (ATR) 0.21 1.07
MACD 0.01 -0.09
Stochastic Oscillator 43.81 34.61

Price Performance

Historical Comparison
VTSI
KLRS

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: